A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week, Dose-Range-Finding Trial of YKP10811 Capsules Administered Once Daily to Subjects With Chronic Idiopathic Constipation

Inclusion Criteria:

- Patients who meet modified Rome II criteria for Chronic Constipation.

- Patients who are male or female, 18 to 65 years of age inclusive.

- At Visit 3, patients must have < 3 CSBMs per week and ≤ 5 SBMs per week during the
2-week baseline period.

Exclusion Criteria:

- Patients who meet Rome II criteria for Irritable Bowel Syndrome (IBS-C).

- Patients with constipation that is drug-induced, or secondary to endocrine, metabolic
or, surgery.

- Patients with a clinically significant diseases that would limit the patient's
ability to complete and/or participate in the study, including gastrointestinal
disorder or surgery, an endocrine abnormality (e.g., diabetes), impaired renal
function (GFR of < 55mL/minute/1.73m2), uncontrolled pulmonary diseases (including
asthma), uncontrolled cardiovascular disease (a history of myocardial infarction or
cerebrovascular accident within 6 months prior to screening) or significant
neurological diseases.

- Patients with a history of inflammatory bowel disease.

- Patients with a history of cancer (other than basal cell or squamous cell carcinoma
of the skin completely excised) unless the malignancy has been in complete remission
for at least 5 years prior to screening.

- Patients who started a special diet and/or an intense physical workout program within
30 days prior to the beginning of the baseline period or who are intending to
substantially modify their dietary habits at any time during the study (patients on a
stable, continuous regimen of fiber therapy for at least 30 days prior to the
pretreatment baseline period are allowed to continue that therapy, provided that they
continue at a constant dose throughout the study.

- Patients with a history of clinically significant hypersensitivity or allergy (facial
swelling, hives, breathing difficulty, Stevens-Johnson syndrome etc), in response to
any medication, either prescription or nonprescription including an investigational
drug, dietary supplement, or herbal medicine.